Last updated: 01/12/2022 07:20:11

Questionnaire-based, Post-Market Clinical Follow-Up (PMCF) Study to Assess the Safety and Performance of Otrisal 0.74 percent (%) Sodium Chloride (NaCl) Metered-Dose Spray (MDS)

GSK study ID
218234
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Observational, Questionnaire-based, Post-Market Clinical Follow-Up (PMCF) Study for Otrisal 0.74% NaCl Metered-Dose Spray
Trial description: The purpose of this study is to further confirm the safety and performance of Otrisal 0.74% NaCl MDS post- Certification Europe (CE) Mark for its indicated populations.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Proportion of Participants who Reported Adverse Event (AE) or Device Malfunction in Previous 6 Months

Timeframe: 6 months prior to completing the online questionnaire

Percentage of Participants Reporting Satisfaction

Timeframe: 6 months prior to completing the online questionnaire

Secondary outcomes:
Not applicable
Interventions:
  • Device: Otrisal 0.74% NaCl MDS
  • Enrollment:
    637
    Primary completion date:
    2021-30-12
    Observational study model:
    Ecologic or Community
    Time perspective:
    Retrospective
    Clinical publications:
    Not applicable
    Medical condition
    Common cold
    Product
    sodium chloride
    Collaborators
    Not applicable
    Study date(s)
    December 2021 to December 2021
    Type
    Observational
    Phase
    4

    Participation criteria

    Sex
    Female & Male
    Age
    0 - 0 Not applicable
    Accepts healthy volunteers
    No
    • Participant (parent/guardian/caregiver [refers to persons over the age of 18 years old] thereof) is reasonably able to operate an electronic resource (for example, access to computer, smartphone or tablet and sufficient Internet access to connect to study platform) and complete the questionnaire in an electronic format.
    • Adults (refers to persons over the age of 18 years old) who have administered or supervised the use of the medical device in infants/babies (including babies less than [<]2 weeks old) or children (parents/guardians/caregiver thereof) in the previous 6 months.
    • Participant (parent/guardian/caregiver thereof) is unable to operate an electronic resource (for example, access to computer, smartphone or tablet and sufficient Internet access to connect to study platform) and complete the questionnaire in an electronic format.
    • Participant (adult/parent/guardian/caregiver thereof) has not used or supervised the use of Otrisal 0.74% NaCl MDS in the previous 6 months.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    Netherlands, Netherlands, Netherlands
    Status
    Study Complete

    Study documents

    No study documents available.

    Results overview

    No study documents available

    Recruitment status
    Study complete
    Actual primary completion date
    2021-30-12
    Actual study completion date
    2021-30-12

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website